AMCP 2017

Specialty drug pipeline predictions: Seven key areas to watchThe specialty drugs market will see more approvals in 2017 than 2016. Top areas to watch include cancer, multiple sclerosis, and HIV.
Highly specific indications dominate cancer drug pipelineRecent and pending drug approvals emphasize the growing importance of niche agents for very specific cancer patient populations.
Monetary benefits from value-based diabetes plans take timeValue-based insurance designs for diabetes care improve outcomes, but monetary gains may take years.
Incremental clinical advances for Duchenne Muscular DystrophyJust last year, the FDA approved Exondys 51 (eteplirsen) for DMD, over the recommendations of FDA scientists and an external scientific advisory committee. Read more.
Rapid oncology innovation raises management challenges for payersOncology is a complex and rapidly-evolving management challenge for payers.
Top challenges likely to slow adoption of biosimilarsBiosimilars will reshape clinical care and managed care pharmacy but ambiguities in the regulatory landscape and knowledge gaps among clinicians seem likely slow adoption.
Top considerations when determining whether to approve expensive drugsWeighing the ethics of approving expensive cancer drugs for patients facing terminal disease is a multifaceted endeavor. Here are some recommendations.
Expedited FDA approval plays dominant role in drug approvalsLast year was a banner year for generic drug approvals by the FDA. Find out what’s in store for 2017.
Predictive analytics reduces chemotherapy-associated hospitalizationsPatient risk can improve value-based cancer care. Find out how.
Payers strategize to manage opioid useHow managed care organizations manage opioid utilization and some of the limitations to those management strategies was a hot topic at the AMCP Annual Meeting.